Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 17, 2024 -- Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the Annals of Hematology.
Dina N. Laimon, M.D., from Mansoura University in Egypt, and colleagues examined the incidence of different ophthalmological manifestations in newly diagnosed acute leukemia in a cross-sectional study involving 222 newly diagnosed acute myeloid and acute lymphoblastic leukemia patients (144 and 78, respectively) who presented between January 2022 and February 2023. All patients underwent a complete ophthalmic evaluation.
The researchers found that ophthalmic manifestations were detected in 43.2 percent of patients. Of these, 1.8 percent had poor visual acuity. The most common ocular manifestations were retinal hemorrhage and Roth spots (19.8 and 17.1 percent, respectively). Other ophthalmological manifestations included orbital involvement, ocular motility issues, subconjunctival hemorrhage, conjunctival chemosis, and lid swelling (3.2, 1.4, 5.9, 0.9, and 4.1 percent, respectively). Compared with acute lymphoblastic leukemia patients, acute myeloid leukemia patients had a significantly higher frequency of ocular affection, retinal hemorrhages, and Roth spots. A significant association was seen for retinal hemorrhage with anemia.
"Cooperation between ophthalmologists and hemato-oncologists is crucial for recognizing ocular involvement and disease management," the authors write. "We need further evaluation of a larger cohort of acute leukemia patients especially for survival analysis to set the record for the prognostic value of ocular manifestations in such neoplasms."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Self-Imposed Use Cessation Dates Tied to Ophthalmic Drop Waste
TUESDAY, July 16, 2024 -- Self-imposed use cessation dates (SUCD) for multiuse eye drop bottles leads to significant drug waste and associated costs, according to a report...
Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
WEDNESDAY, July 3, 2024 -- Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with...
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
MONDAY, June 24, 2024 -- For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.